Medivation, Inc.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe. The company’s lead development candidate includes MDV3100, a molecule, which is in Phase-III development for the treatment of castration-resistant prostate cancer.

Ticker:
MDVN
Exchange:
NASDAQ (See More NASDAQ Companies)
Sector:
Healthcare (See More Healthcare Companies)